Everyone Blames the Opioid Settlement. CVS Decided to Close the Stores a Year Earlier.

On November 17, 2021, CVS's board did something quiet and consequential: it authorized closing roughly 900 stores, about 300 a year for three years, and booked an impairment charge of up to $1.2 billion against them.¹ No scandal triggered it. No verdict forced it. It was a planning decision, the kind that lives in an 8-K and gets read by a few analysts. Eleven months later, CVS agreed to pay about $5 billion over a decade to settle opioid lawsuits⁴ — and the public quietly stitched the two events together into a single story of a company paying for its sins. That story is wrong, and the date proves it.

The popular framing is that the opioid settlement broke CVS's stores. It didn't. The board ordered the closures a full year before the settlement existed, and the real cause was something far less dramatic and far harder to fix: the money a CVS store makes had been bleeding out, slowly, for the better part of a decade.

The margin fell for eight years before anyone called it a crisis

Strip away the headlines and look at the one number that decides whether a store is worth keeping open. CVS's pharmacy and consumer wellness operating margin was 9.9% in 2015. By 2019 it had slid to 8.5%. By 2023 it had collapsed to 4.6% — less than half what it was eight years earlier.⁷ That is not a shock. That is erosion. And erosion has two engines, both named plainly in CVS's own filings: prescription reimbursement rates that keep falling, and front-store traffic that keeps shrinking.⁸ The pharmacy fills the script for less money each year. The aisles in front of it sell fewer greeting cards and shampoo bottles to people who now buy them online. A store living on those two flows is a store running out of reasons to exist.

Here is the mechanism, worked all the way down. A drugstore's economics rest on a simple bet: a pharmacy counter that throws off enough margin to subsidize a retail floor that pulls people in. When the reimbursement on a filled prescription drops year after year, the counter stops subsidizing — it starts needing subsidy itself. And when the retail floor's traffic decays at the same time, there is nothing left to do the subsidizing. The two pillars lean on each other, and both were buckling at once. CVS didn't close 900 stores because it suddenly owed money to states. It closed them because the unit economics of a corner drugstore had quietly stopped working, and the company had thousands of corners.

Why the opioid number is a story, not a cause

It is tempting to treat the $5 billion as the wound. The combined CVS and Walgreens opioid settlements totaled $10.7 billion, with CVS's share about $5 billion.⁵ A frightening figure — until you do the arithmetic on it. CVS agreed to pay it over ten years, roughly $500 million a year, against total revenues of $372.8 billion.³ That is a real cost and a manageable one: a rounding error on the top line, paid in slow installments. A company does not dismantle a tenth of its physical footprint to cover something that costs it about a seventh of one percent of revenue annually. The settlement is a line item. The margin is the disease.

The confusion deepens because there are two closure programs, not one, and they get blended into a single headline. The original 2021 plan covered roughly 900 stores through 2024. Then, in the third quarter of 2024, CVS finalized a separate enterprise-wide restructuring and decided to close 271 additional stores in 2025, taking a $747 million charge for it.² That is a distinct decision on top of the first — bringing the combined total to roughly 1,171. And even after all of it, CVS still operated more than 9,000 locations at the end of 2024.⁶ The retrenchment is real, but it is a pruning, not an amputation: a chain shedding the densest, least productive parts of an oversized footprint while keeping the bulk of the network intact.

But couldn't the settlement have been the last straw?

The honest objection is that timing isn't everything — that even if the closures were authorized first, the looming opioid liability could have hardened management's resolve to retrench, making it a real contributing pressure rather than pure coincidence. That's fair, and worth granting. A board staring at a multibillion-dollar overhang is a board more willing to cut. But contributing pressure is not operative cause, and the filings keep pointing at the same two culprits regardless of the legal weather: reimbursement and traffic.⁸ The 2024 restructuring that produced the 271 additional closures was driven by the same margin math, not by a settlement signed two years earlier. When operating income fell 38% in 2024, CVS attributed it to weaker adjusted operating income and higher restructuring charges³ — the cost of the cutting, not the cost of the lawsuit. The settlement may have sharpened the knife. It did not write the diagnosis.

CVS's retrenchment is the most ordinary kind of fall — not a single catastrophe but a slow arithmetic that finally forced a decision. The pharmacy counter stopped subsidizing the store, the store stopped pulling its weight, and a company with thousands of corners did the math on each one. The opioid settlement gave the public a clean, moral story to hang it on, and that story does the real one a quiet disservice: it lets everyone believe the problem was a one-time sin that's been paid for, when the problem is a business model that earns less every year for filling the same prescription. The stores didn't close because CVS got caught. They closed because the corner drugstore quietly stopped making money — and the settlement was just the loudest thing in the room when the bill came due.